Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and 1:2 ratio matched infection-naïve cohort who received two injections. The evaluation procedure included symptom monitoring, and serological tests. Among the post-infected population, the median IgG-S response after the first vaccine dose was 3.35 AU, compared to 2.38 AU after the second vaccine injection in the infection naive group. A strong correlation was demonstrated between IgG-S level before vaccination, and the corresponding responses after a single vaccine dose (r = 0.8, p < 0.001) in the post infected population. Short-term severe symptoms that required medical attention were found in 6.8% among the post-infected individuals, while none were found in the infection naïve population. Our data suggest that a single vaccine dose is sufficient to induce an intense immune response in post-infected population regardless of seropositivity. Although some short-term safety issues were observed compared to the infection naïve population, a single dose regimen can be considered safe in post-infected populations.
【저자키워드】 viral infection, Vaccines, 【초록키워드】 COVID-19, Efficacy, COVID-19 vaccine, immune response, vaccination, Infection, risk, Symptom, Population, vaccine dose, BNT162b2, Reinfection, Cohort, Serological tests, mRNA, response, Seropositivity, correlation, serological, BNT162b2 mRNA COVID-19 vaccine, single dose, dose, Safe, regimen, individual, naïve, Injections, mRNA-based vaccines, mRNA-based vaccine, single vaccine, populations, required, demonstrated, induce, individuals, severe symptom, of BNT162b2, the median, vaccine injection, 【제목키워드】 SARS-CoV-2, Safety, Population, Humoral response, BNT162b2 mRNA vaccination,